New drug combo aims to keep breast cancer from returning to the brain
NCT ID NCT05323955
Summary
This study is for people with advanced HER2+ breast cancer whose cancer has spread to the brain but is stable elsewhere. It tests if adding the drug tucatinib to their current standard treatment can help keep the brain tumors from growing back longer. About 48 participants will receive the new combination and be monitored to see how long their brain disease stays controlled and to check for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
-
University of California San Francisco
San Francisco, California, 94158, United States
-
University of Michigan Health System
Ann Arbor, Michigan, 48109, United States
-
Washington University in St. Louis
St Louis, Missouri, 63130, United States
Conditions
Explore the condition pages connected to this study.